FGK Clinical Research GmbH (FGK), a European, full-service contract research organization has entered into a multi-year partnership with OmniComm Systems, Inc., an Anju Software company and a global provider of patient-centric, clinical data management technology. Under the terms of the agreement, FGK will use TrialMaster electronic data capture (EDC), IRTMaster (web-based self-service clinical supply management and randomization), and Acuity Analytics (data visualization and risk-based monitoring) along with other related products/services to supplement FGK’s clinical trial operational and data management services to pharmaceutical, biotechnology and medical device companies.
“It’s very rewarding for OmniComm to be able to deliver a myriad of fully integrated eClinical solutions that align perfectly with our client’s needs,” says Stephen Johnson, chief revenue officer of OmniComm. “We look forward to a rapid adoption and working together with FGK to simplify the clinical research process for their clients.”
The Munich based company selected OmniComm’s technology suite for its user-friendly interface and streamlined user management, with the added benefit of seamless data integration across the EDC and IRT systems, eliminating redundancy in data entry and improving efficiency for investigative sites. The implementation and onboarding process will be managed locally, and all training will be delivered by OmniComm’s professional services group based out of its German office in Bonn.
“It is an important step for FGK to strengthen our abilities in clinical trials with the eSolutions of OmniComm. FGK has very challenging projects and OmniComm’s products perfectly fit to our strategy to apply best solutions on latest technology,” says Managing Director Martin Krauss. “We look forward to the partnership with OmniComm for the benefit of our Client’s projects.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.